MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012, causing over 1800 infections and 650 deaths globally.
• No approved vaccines or therapeutics are currently available for MERS-CoV.
• The MERS-CoV spike (S) protein is crucial for viral entry and is a key target for vaccine development due to its immunodominance and ability to elicit neutralizing antibodies.

Purpose of the Study:

• To evaluate the efficacy of a recombinant MERS-CoV S nanoparticle vaccine combined with Matrix-M1 adjuvant in a mouse model.
• To assess the immunogenicity and protective capabilities of the developed vaccine candidate against MERS-CoV infection.

Main Methods:

• Development of a recombinant MERS-CoV S nanoparticle vaccine.
• Combination of the S nanoparticle vaccine with the Matrix-M1 adjuvant.
• Vaccination of mice with the MERS-CoV S nanoparticle vaccine and adjuvant combination.
• Assessment of anti-S neutralizing antibody titers and protection against MERS-CoV infection in vivo.

Main Results:

• The MERS-CoV S nanoparticle vaccine induced high titers of anti-S neutralizing antibodies in vaccinated mice.
• Vaccination conferred significant protection against MERS-CoV infection in the mouse model.
• The combination of the S nanoparticle vaccine with Matrix-M1 adjuvant demonstrated protective efficacy.

Conclusions:

• The recombinant MERS-CoV S nanoparticle vaccine with Matrix-M1 adjuvant is a promising candidate for a MERS-CoV vaccine.
• This vaccine strategy effectively elicits neutralizing antibodies and provides protection against MERS-CoV infection in mice.
• Further research into this vaccine approach could lead to a viable therapeutic option for MERS-CoV.